新消息！美国最大养老基金反对马斯克560亿美元薪酬方案：巨额激励引争议

美国最大养老基金反对马斯克560亿美元薪酬方案：巨额激励引争议

北京讯 – 美国最大公共养老基金加州公务员退休基金（CalPERS）周三宣布，将反对特斯拉首席执行官埃隆·马斯克的560亿美元薪酬方案。这一决定可能对马斯克的薪酬计划产生重大影响，并引发了关于高管薪酬过高的更广泛讨论。

CalPERS拥有约950万股特斯拉股票，是该公司市值前30大投资者之一。该基金表示，马斯克的薪酬方案“过高”，并“与CalPERS长期以来对高管薪酬的看法不符”。

CalPERS的反对并非孤例。挪威主权财富基金和美国加州两大养老基金此前也表示将反对该薪酬方案。这些反对意见主要集中在以下几个方面：

• 薪酬额度过高：马斯克的薪酬方案价值560亿美元，是美国公司历史上最大的薪酬方案之一。一些投资者认为，这一数额与特斯拉的实际业绩并不相符，也无法体现对所有股东的公平。
• 缺乏透明度：马斯克的薪酬方案基于一系列复杂的目标，包括特斯拉的股价和市值增长。一些投资者认为，这些目标过于模糊，缺乏透明度，使得评估马斯克的绩效和薪酬合理性变得困难。
• 对公司治理的担忧：一些投资者担心，马斯克的薪酬方案会给他带来过大的权力，并可能损害公司治理。

马斯克的薪酬方案于2018年由特斯拉董事会批准。该方案授予马斯克12组股票期权，如果他能够实现所有目标，这些期权的价值将达到560亿美元。马斯克已经实现了一些目标，并因此获得了数十亿美元的收益。

特斯拉董事会辩护称，马斯克的薪酬方案是必要的，因为它激励他实现了特斯拉的雄心勃勃目标，并使该公司成为世界上最有价值的汽车制造商之一。然而，批评人士认为，马斯克已经从特斯拉的成功中获得了巨大收益，他的薪酬应该与普通员工的薪酬水平更加接近。

马斯克的薪酬方案将在6月7日举行的特斯拉股东大会上进行表决。目前尚不清楚该方案能否获得通过。即使获得通过，CalPERS和其他投资者的反对意见也可能对马斯克的声誉和特斯拉的股价造成负面影响。

以下是一些其他值得关注的细节：

• 马斯克是特斯拉的首席执行官、产品架构师和首席工程师。他也是太空探索公司SpaceX的创始人、首席执行官和首席技术官，以及脑机接口公司Neuralink的联合创始人。
• 特斯拉在2023年实现了几项重大目标，包括交付超过100万辆汽车、实现盈利以及进入新的市场。
• 马斯克是一位颇具争议的人物。他经常发表引人注目的言论，并在社交媒体上与他人发生争执。

这篇文章是对以下信息的扩充和洗稿：

• 美国最大养老基金确认将投票反对马斯克薪酬方案
• 年薪高达560亿美元！马斯克宣布赢得薪酬方案投票
• CalPERS CEO：将投票反对特斯拉CEO马斯克560亿美元薪酬方案

A Wave of "Kete Valuation" Sweeps Through the Market: 50 Stocks Poised for Strong Growth

Shanghai, China - June 17, 2024 - A recent surge in investor sentiment towards growth stocks, particularly in the healthcare and technology sectors, has been dubbed the "Kete Valuation" phenomenon, named after the Chinese pharmaceutical company C-Bridge (6160.HK). This trend is reminiscent of the "CATL Valuation" rally that occurred in 2021, driven by the strong performance of Contemporary Amperex Technology Co., Ltd. (300015.SZ).

The "Kete Valuation" is characterized by a sharp increase in the share prices of companies with promising growth prospects, often defying broader market trends. This is evident in the recent performance of 50 stocks identified by analysts as having significant growth potential. These stocks, spanning various industries including healthcare, technology, and consumer goods, have exhibited remarkable resilience amidst recent market volatility.

Factors Driving the "Kete Valuation"

Several factors are contributing to the "Kete Valuation" trend. Firstly, investors are increasingly seeking out companies that can deliver sustainable growth, particularly in the face of global economic uncertainties. Secondly, the easing of monetary policy in major economies is providing a supportive backdrop for riskier assets like growth stocks. Additionally, advancements in technology and innovation are creating new opportunities for companies in various sectors, fueling investor optimism.

Key Beneficiaries of the "Kete Valuation"

Among the 50 stocks identified as potential beneficiaries of the "Kete Valuation," C-Bridge (6160.HK) stands out as a frontrunner. The company's innovative cancer therapies and strong pipeline of new drugs have attracted significant investor interest. Other notable stocks include:

• Ascletis Pharma (1672.HK): A clinical-stage biopharmaceutical company developing novel therapies for cancer and viral diseases.

• Aier Eye Hospital Group (300015.SZ): A leading provider of comprehensive eye care services in China.

• Xiaomi Corporation (1810.HK): A global technology company known for its smartphones, smart home devices, and internet services.

Investment Implications

The "Kete Valuation" presents an opportunity for investors to capitalize on the growth potential of select companies. However, careful due diligence is crucial, as not all growth stocks are created equal. Investors should thoroughly evaluate a company's financial health, competitive landscape, and long-term growth prospects before making investment decisions.

The "Kete Valuation" highlights the evolving dynamics of the Chinese stock market, where investors are increasingly discerning and seeking out companies with genuine growth potential. This trend is likely to continue as China's economy transitions towards a more innovation-driven and knowledge-based model.